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Abstract 
Development of psychiatric symptoms during interferon-alpha (IFN-α) therapy may be 
influenced by psychological factors. We examined illness perceptions using The Revised 
Illness Perceptions Questionnaire (IPQ-R) in 55 patients with chronic Hepatitis C virus 
infection, due to receive IFN-α. The Hospital Anxiety and Depression Scale (HADS) was 
used to assess the development of symptoms. Negative identity, consequences and 
emotional representations beliefs were significantly associated with both higher 
depression and anxiety scores. Negative illness perceptions play a predictive role in the 
development of IFN-α-induced psychiatric symptoms. 
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Introduction 
Interferon-alpha (IFN-α) therapy for chronic hepatitis C virus (HCV) infection is 
associated with the development of depression and other neuropsychiatric adverse 
effects (Sockalingam and Abbey, 2009). Depression is the most commonly observed 
neuropsychiatric symptom during IFN-α therapy with an incidence of up to 45% (Asnis 
and De La Garza, 2006, Capuron and Miller, 2004, Raison et al., 2005b). There has been 
less focus on the development of anxiety. However, a recent study reported 46.6% of 
patients met criteria for generalized anxiety disorder following 12 weeks of IFN-α 
treatment (Bassiony et al., 2015). When the incidence of depressive and anxiety 
symptoms are combined, the cumulative incidence can be as high as 60% (Evon et al., 
2008, Fontana, 2000, Kraus et al., 2003). 
 
In recent years, extensive research has been conducted into understanding and 
detecting different risk factors associated with the development of neuropsychiatric 
side effects during IFN-α treatment. Demographic and clinical risk factors for the 
development of IFN-α-induced depression include a history of major depressive disorder 
(Castera et al., 2006, Raison et al., 2005a) and the presence of mood or anxiety 
symptoms prior to treatment (Dieperink et al., 2003, Evon et al., 2009, Lotrich et al., 
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2007). More recently, a large-scale study showed that a psychiatric history was a strong 
risk factor for the development of both depression and anxiety during treatment (Masip 
et al., 2015). However, little research has focused on understanding the role of 
psychological factors. Well-defined predictors of the development of IFN-α-induced 
neuropsychiatric side effects, which are independent from previous or current 
psychopathology, are still lacking. 
 
A biopsychosocial model of health and illness may be helpful in understanding the 
psychological distress associated with IFN-α therapy. One of the most widely researched 
models of health and illness is Leventhal’s self-regulatory model. This model emerged 
from a series of studies where high fear messages were consistently found to be more 
effective in changing attitudes toward a recommended health action in comparison to 
low fear messages (Leventhal, 1970). The model is based on the notion that individuals 
are active problem solvers dealing with the perceived reality of a health threat as well 
as their emotional reactions to this threat (Leventhal et al., 1980). Accordingly, they 
make sense of a threat to their health and determine how to respond by developing 
their own cognitive representations of the threat. These cognitive representations, also 
known as illness perceptions, are a patient’s own common sense beliefs about their 
5 
 
illness. The manner in which patients perceive their illness and subsequent therapy is 
likely to influence many aspects of their experience including side-effects (such as 
developing depression or anxiety) and other health outcomes. As such, examining 
domains of illness perceptions may provide useful information for the development of 
interventions aimed at reducing the occurrence of these symptoms.  
 
Across disease groups, and particularly in chronic disorders, illness perceptions have 
been found to be associated with several emotional well-being and quality of life 
outcomes (Bonsaksen et al., 2015, Endermann and Zimmermann, 2009, Rochelle and 
Fidler, 2013). A meta-analysis has demonstrated a salient relationship between 
cognitive illness perceptions and a range of emotion focussed coping behaviours across 
23 health conditions (Hagger and Orbell, 2003). In specific conditions such as myocardial 
infarction, negative illness perceptions have been shown to contribute to the 
development of subsequent new episodes of depression (Dickens et al., 2008). This has 
also been demonstrated in chronic conditions such as multiple sclerosis, psoriasis, 
diabetes and irritable bowel syndrome (Fortune et al., 2002, Jopson and Moss-Morris, 
2003, Paschalides et al., 2004, Rutter and Rutter, 2002). Research on individuals with 
well-defined diseases has shown in particular that a strong illness identity, a long 
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timeline perspective, and serious consequences are associated with more negative 
health outcomes (Hagger and Orbell, 2003). 
 
Illness perceptions have not previously been investigated in patients with HCV infection 
treated with IFN-α. The aim of this study was to test the hypothesis that negative illness 
perceptions (as defined by a greater number of associated symptoms, greater perceived 
duration and cyclical nature, more perceived consequences, less perceived personal and 
treatment control, less illness coherence and greater emotional responses) about HCV 
infection prior to starting IFN-α therapy will be associated with the development of 
increased depressive and anxiety symptoms during treatment. 
 
Materials and methods 
Study design and participant selection 
A prospective cohort design was used to investigate the effects of IFN-α therapy. 
Patients were evaluated at baseline (week 0) and after 4, 8, 12, 16, 20 and 24 weeks of 
IFN-α treatment. All data were collected in the presence of a trained researcher during 
monthly outpatient appointments which participants attended as part of their IFN-α 
therapy. For convenience, participants were given the option of completing follow-up 
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self-report questionnaires at home prior to their appointment, followed by a shorter 
face-to-face interview with a researcher. In these cases, questionnaires were sent to 
participants via post a few days prior to their appointment and they were then asked to 
bring their completed questionnaires with them to their appointment. We recruited and 
assessed a total of 55 participants. Participants were recruited from the outpatient liver 
departments of three London hospitals: King’s College Hospital, Guy’s and St. Thomas’ 
Hospital and St. George’s Hospital. Eligible participants were adult patients with chronic 
HCV infection who were due to commence combination antiviral therapy with IFN-α and 
ribavirin. All patients were scheduled to receive combination therapy for at least 24 
weeks. This comprised of weekly subcutaneous IFN-α injections (1.5 μg per kg of body 
weight) and daily ribavirin tablets (800 to 1400 mg orally per day in 2 divided doses). 
Exclusion criteria included age below 18 years, autoimmune disorder, cause for liver 
disease other than HCV, current use of antidepressants, lack of English language and co-
infection with HIV or hepatitis B. Written informed consent was obtained from all 
participants after a complete explanation of the study, a presentation of a participant 
information sheet and an opportunity to ask questions. The study was approved by the 
King’s College Hospital Research Ethics Committee (Ref: 10/H0808/30). 
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Sociodemographics and psychiatric history 
In order to identify potential risk/predictive factors for the development of IFN-α-
induced depression and anxiety, some assessments were conducted by a trained 
interviewer at the baseline, immediately before IFN-α therapy. These included the 
collection of socio-demographic data using a modified version of the MRC 
Sociodemographic Schedule (Mallett et al., 2002). Dichotomised variables were created 
to consolidate multiple classes of data for: ethnicity; level of education; current 
relationship status and current employment status. A previous history of major 
depressive disorder was assessed using the relevant section of the Mini International 
Neuropsychiatric Interview (MINI). The MINI is a structured diagnostic interview for 
psychiatric disorders according to the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV) and the International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10) (Sheehan et al., 1998). 
  
Measure of illness perceptions 
Information regarding illness perceptions was collected using The Revised Illness 
Perceptions Questionnaire (IPQ-R) (Moss-Morris et al., 2002). We used the first two 
sections of the IPQ-R: the first section examines illness identity (the symptoms the 
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individual associates with the illness) and the second section examines participants’ 
beliefs about their illness. This second section is comprised of the domains of timeline 
(acute/chronic and a cyclical subscale), consequences (expected effects and outcome), 
personal and treatment control (beliefs about potential for cure and control of the 
illness), illness coherence and emotional representations (Weinman et al., 1996). Higher 
scores indicate a strong identity, perception that the illness is chronic and that it is cyclic 
in nature, that it has serious consequences, that control or cure is possible, that the 
individual has a good understanding of their illness and a strong emotional response.  
 
Measure of depressive and anxiety symptoms 
The presence and severity of depressive and anxiety symptoms were assessed at 
baseline and at every subsequent monthly assessment during the course of IFN-α 
therapy using the Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 
1983). The HADS is a widely used 14-item self-report scale designed to briefly measure 
current anxiety and depressive symptomatology in non-psychiatric hospital patients. It 
excludes somatic symptoms, therefore avoiding potential confounding by somatic 
symptoms. There are independent subscales for anxiety and depression each comprised 
of 7-items designed to screen for the presence and severity of symptoms over the past 
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week. Items are scored on a 0-3 scale to give a total score range of 0-21. Scores in the 
range of 0-7 are considered normal; 8-10, mild; 11-14, moderate; and 15-21, severe. 
 
Data analyses 
Data were analyzed using IBM SPSS statistical software version 20 and STATA version 
11. Continuous variables are presented as mean ± standard errors. Pearson correlation 
analyses and one-way analyses of variance were conducted to evaluate continuous and 
categorical variables as covariates of depression and anxiety scores. Given the relatively 
small sample size, only significantly correlated variables were retained as covariates in 
the main regression analyses. Random intercept regression models with maximum 
likelihood effects were used to investigate the predictive effects of illness perceptions 
dimensions on changes in depression and anxiety scores as a function over time. The 
dataset is changed from wide to long format and clustered by individual. This method of 
analysis is an ideal way to model repeated measures.  
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Results  
Sample characteristics and symptomatology 
All 55 participants completed the baseline and three follow-up assessments (up to 
treatment week 12). The socio-demographic and disease characteristics of the sample 
are presented in Table 1. The disease characteristics include: HCV genotype, baseline 
viral load (that is, the number of viral particles per ml of blood presented in millions) and 
the severity of liver disease as measured by a fibroscan and rated in kilopascals (KPa). At 
baseline, no participants met criteria for a current MDD diagnosis. However, 18 
participants (33%) had a self-reported history of MDD and 14 (26%) had a family history 
of psychiatric illness. Both depression and anxiety scores increased significantly over the 
course of IFN-α treatment (Coefficient=0.14, p<0.001 and Coefficient=0.04, p=0.027, 
respectively). The proportion of participants meeting criteria for mild, moderate and 
severe depression and anxiety during IFN-α therapy is presented in Table 2. Only 2 
participants were started on anti-depressant treatment during the course of the study.  
[INSERT HERE TABLE 1] 
[INSERT HERE TABLE 2] 
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Covariates of depression and anxiety 
In line with findings from previous studies, baseline depression scores were associated 
with subsequent depression scores at all treatment weeks (r=0.46-0.58, all p<0.01) and 
with subsequent anxiety scores at all treatment weeks (r=0.35-0.56, all p<0.01). 
Similarly, baseline anxiety scores were associated with subsequent depression scores 
specifically at treatment weeks (TW)4, TW12, TW20 and TW24 (r=0.35, r=0.36, r=0.33, 
r=0.44, respectively, all p<0.05) and with subsequent anxiety scores at all treatment 
weeks (r=0.51-0.63, all p<0.01). A previous history of depression was associated with 
subsequent anxiety scores at TW4, TW8, TW16 and TW20 (F=5.98, F=10.24, F=6.71, 
F=4.56, respectively all p<0.05) but not with depression scores. Furthermore, age was 
also negatively associated with subsequent anxiety scores at TW4 and TW8, (r=-0.29 and 
r=-0.33, both p<0.05) but again not with depression scores. As such, baseline depression 
scores, baseline anxiety scores, previous history of depression and age were retained as 
covariates in subsequent regression analyses for anxiety. Only baseline depression 
scores and baseline anxiety scores were retained as covariates for subsequent 
regression analyses for depression. No other socio-demographic factors were associated 
with either depression or anxiety scores. 
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Illness perceptions as predictors of depression 
To establish illness perceptions domains as possible predictors of higher depression 
scores, we ran a separate regression analysis for each illness perceptions domain, 
adjusting for relevant covariates (baseline depression scores and baseline anxiety 
scores). The results demonstrated that, even after adjusting for these covariates, three 
illness perceptions domains (identity, consequences and emotional representations) 
continued to account for significant variance in depression scores with a trend also for 
the timeline domain (See Table 3).  
[INSERT HERE TABLE 3] 
 
Illness perceptions as predictors of anxiety 
To establish illness perceptions domains as possible predictors of higher anxiety scores, 
we again ran a separate regression analysis for each illness perceptions domain, 
adjusting for relevant covariates (baseline depression scores, baseline anxiety scores, 
previous history of depression and age). The results demonstrated that, even after 
adjusting for these covariates, four illness perceptions domains (identity, consequences, 
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timeline cyclical and emotional representations) continued to account for significant 
variance in anxiety scores (See Table 4). 
[INSERT HERE TABLE 4] 
 
Discussion 
This is the first study to investigate the role of illness perceptions on the development 
of depressive and anxiety symptoms during interferon-alpha (IFN-α) treatment. We 
demonstrate predictive effects of illness perceptions on higher depression and anxiety 
scores during treatment. Specifically, we show that negative beliefs in the identity, 
consequences, timeline cyclical, and emotional representations dimensions predict 
higher anxiety scores, with identity, consequences and emotional representations also 
having a predictive effect on higher depression scores. In other words, having a strong 
illness identity, believing your illness will have more serious consequences and having a 
strong emotional response to your illness, are all predictive of both depression and 
anxiety. Moreover, we demonstrate that these effects are independent of previous 
psychopathology. 
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These findings are in keeping with previous studies conducted in other populations also 
showing associations between illness identity as well as strong perceived consequences 
and timeline to be predictive of poorer health outcomes (Bijsterbosch et al., 2009, Foster 
et al., 2008, Keeling et al., 2013, Scharloo et al., 2000). Studies examining psychological 
adjustment to illness have also shown that patients who perceive their illness as having 
serious consequences, a strong illness identity and chronic timeline have negative 
associations with physical, social and role functioning (Heijmans and de Ridder, 1998, 
Scharloo et al., 1998). Previous research has also demonstrated the impact of illness 
perceptions on outcomes following medical treatment. Again, more negative perceived 
consequences were shown to be associated with poorer emotional well-being outcomes 
in men following cancer treatment (Traeger et al., 2009). A recent meta-analysis on 
diabetes, a condition which presents frequent comorbidity with depression and anxiety, 
also showed increased beliefs about consequences to be associated with poorer 
emotional health symptoms as demonstrated by higher depression scores (Hudson et 
al., 2014). The authors also found identity and timeline beliefs to be associated with 
anxiety but not depression which, like our findings, suggest there may be differences 
across emotional states. In the context of HCV infection, it is possible that negative 
illness perceptions may be influenced by the associated stigma. Indeed, a recent 
qualitative study investigating patient experiences of undergoing IFN-α treatment in 
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those with a history of mental health problems, identified stigma and fear of being 
judged as a key theme (Ware et al., 2015).  
 
There may be biological and psychological underlying mechanisms which potentially 
drive the association between negative illness perceptions and higher depression and 
anxiety scores. Two possible (not mutually exclusive) biological mechanisms are 
increased inflammation and abnormal hypothalamic-pituitary-adrenal (HPA) axis 
activity. Alterations of the stress response system indicated by abnormal HPA axis 
activity, is a well-established and consistent finding in depression (Pariante and Miller, 
2001). Similarly, there is also a wealth of evidence to support the role of psycho-
neuroimmunological dysfunctions in the pathophysiology of depression where there is 
activation of the immune system (Zunszain et al., 2012). Negative emotions are linked 
to the immune system’s adaptive reactions (Steptoe et al., 2008) and much like other 
psychological factors, it is possible that negative illness perceptions relate to immune 
processes in ways similar to general stress. Psychological factors which may underlie the 
association between illness perceptions and increased depression and anxiety may 
include personality traits. Previous research has identified neuroticism to be a predictor 
of IFN-α-induced depression (Lotrich et al., 2007). This is relevant to our findings as 
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neuroticism is associated more generally with pessimism and negative cognitions and 
beliefs. Interestingly, neuroticism has also been shown to be associated with increased 
inflammation (Bouhuys et al., 2004) as well as increased awakening cortisol response 
(Bhagwagar et al., 2005) again suggesting that there is an interplay between 
psychological and biological domains. 
 
These findings are of clinical importance as, unlike other factors such as socio-
demographic variables, these links between beliefs and treatment induced 
neuropsychiatric symptoms provide potential for developing preventive cognitive based 
interventions. Identifying negative thinking associated with the development of 
psychiatric symptoms could help to develop an intervention targeted towards fostering 
more adaptive models and expectations, in order to improve outcomes. Indeed, in other 
populations, interventions aimed at changing illness perceptions have been shown to 
improve functional health outcomes. For example, a brief hospital intervention designed 
to alter patients’ illness perceptions has been shown to improve functional outcomes 
and rate of return to work following myocardial infarction (Petrie et al., 2002). A 
randomized controlled trial of a psychological family-based intervention targeting 
negative and/or inaccurate illness perceptions in patients with type 2 diabetes, found 
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that physical health outcomes as well as psychological well-being were improved in the 
intervention group (Keogh et al., 2011). More recently, a brief cognitive behavioural 
therapy (CBT) intervention in patients with irritable bowel syndrome (IBS) was shown to 
change illness perceptions and improve IBS symptom severity (Chilcot and Moss-Morris, 
2013). In the context of HCV infection and IFN-α therapy, given that prophylactic 
treatment with antidepressants is not always effective and carries risk (Galvao-de 
Almeida et al., 2010, Wu et al., 2007), identifying such targets for clinical intervention is 
imperative. Of note is also that, identifying predictors of IFN-α-induced depression can 
still have a role in clinical practice, even in light of emerging IFN-α free treatment 
regimens. Although, there are new IFN-α free treatment licenced for use in HCV 
infectious (Ryder, 2015), these treatments are not yet readily available for all viral 
genotypes. Furthermore, while these new treatments are highly effective, they are 
expensive. This is a major barrier to access and indeed some have not been approved 
for use in some countries simply due to the financial burden (Ryder, 2015). As such, IFN-
α-induced depression still remains a clinical burden.   
 
There are a few methodological considerations and study limitations that need to be 
considered in the interpretation of these findings. Information about diagnosis of viral 
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illness or duration of untreated HCV infection was not collected. This may be of 
particular importance with regards to illness perceptions, as there may be differences 
between individuals who have had a more recent diagnosis when compared to those 
who have had a longer duration of illness. A second limitation of the study is that the 
baseline assessment was conducted on the first day of treatment, immediately before 
the first administration of IFN-α. As such, it is possible that some of the baseline 
psychopathological ratings as well as illness perceptions responses may have been 
affected by patients’ concerns and anxieties surrounding starting IFN-α treatment. A 
baseline assessment that is more remote from the beginning of therapy initiation may 
be more appropriate. It is also important to note that due to the high number of 
predictor variables, there is a potential for increased type 1 error as multiple 
comparisons were not corrected for. However, frequently used procedures such as the 
Bonferroni method are conservative, not appropriate for a large number of tests and 
diminish statistical power (Bland and Altman, 1995). Furthermore, methods to adjust for 
multiple testing are rare in studies such as this which collect repeated measurements as 
these comparisons occur for between-subject factors, within-subject factors, or both 
(Bender and Lange, 2001).  
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Nevertheless, our study provides evidence for the first time, for a role of illness 
perceptions in the development of increased depression and anxiety symptoms 
following IFN-α therapy. Asking patients about their beliefs and understanding of their 
HCV infection prior to starting treatment, may help to identify more vulnerable 
individuals who require additional support during the treatment process. 
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 Table 1. Socio-demographic and disease characteristics of the sample 
 Patients 
n = 55 
Age (years) 
Mean±SEM 
Range 
 
44.4±1.6 
18-68 
Gender 
Males 
 
42 (76%) 
Ethnicity 
White British 
Other 
 
27 (49%) 
28 (51%) 
Education Level 
University/A Levels 
GCSEs/No Qualifications 
 
21 (40%) 
32 (60%) 
Employment 
Full-time 
Unemployed 
 
31 (56%) 
24 (44%) 
Relationship Status 
Single 
Married/Cohabiting 
 
26 (47%) 
29 (53%) 
History of Depression 18 (33%) 
Family History of Psychiatric Illness 14 (26%) 
HCV Genotype   
1&4 
 
12 (22%) 
28 
 
2&3 43 (78%) 
HCV Viral Load (million) 
Mean±SEM 
 
2.1±0.4 
Fibroscan (kpa) 
Mean±SEM 
 
9.8±1.2 
 
  
29 
 
Table 2 Proportion of participants meeting criteria for mild, moderate or severe 
depression and anxiety during the course IFN-α therapy as indicated by HADS scores 
 Baseline TW4 TW8 TW12 TW16 TW20 TW24 
Depression 
Normal 89% 76% 69% 64% 58% 59% 70% 
Mild 7% 16% 18% 16% 23% 18% 7% 
Moderate 4% 6% 7% 13% 15% 14% 16% 
Severe 0% 2% 6% 7% 4% 9% 7% 
Anxiety 
Normal 81% 82% 73% 76% 73% 68% 71% 
Mild 6% 9% 14% 7% 15% 11% 11% 
Moderate 11% 7% 11% 13% 8% 14% 13% 
Severe 2% 2% 2% 4% 4% 7% 5% 
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Table 3. Random intercept regression models for depression with maximum likelihood 
effects (controlled for baseline depression and baseline anxiety scores) 
IPQ Dimension Coefficient Standard Error p value 
Identity (0-14) 0.24 0.12 0.050 
Timeline (0-30) 0.14 0.08 0.054 
Consequences (0-30) 0.19 0.07 0.007 
Personal control  (0-30) -0.11 0.13 0.392 
Treatment control (0-25) -0.13 0.13 0.329 
Illness coherence (0-20) 0.02 0.11 0.866 
Timeline Cyclical (0-20) 0.17 0.10 0.073 
Emotional Representations (0-30) 0.16 0.08 0.047 
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Table 4. Random intercept regression models for anxiety with maximum likelihood 
effects (controlled for baseline depression and baseline anxiety scores, previous history 
of depression and age) 
IPQ Dimension Coefficient Standard Error p value 
Identity (0-14) 0.26 0.10 0.008 
Timeline (0-30) 0.09 0.07 0.157 
Consequences (0-30) 0.13 0.06 0.025 
Personal control (0-30) -0.15 0.11 0.159 
Treatment control (0-25) -0.10 0.12 0.377 
Illness coherence (0-20) 0.06 0.09 0.483 
Timeline Cyclical (0-20) 0.18 0.09 0.033 
Emotional Representations (0-30) 0.14 0.07 0.040 
 
 
